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Most classical phosphotyrosyl phosphatases (PTPs), including the Src homology phosphotyrosyl phosphatase 2 (SHP2) possess a Thr or a Ser
residue immediately C-terminal to the invariant Arg in the active site consensus motif (H/V-C-X5-R-S/T), also known as the “signature motif”.
SHP2 has a Thr (Thr466) at this position, but its importance in catalysis has not been investigated. By employing site-directed mutagenesis,
phosphatase assays and substrate-trapping studies, we demonstrate that Thr466 is critical for the catalytic activity of SHP2. Its mutation to Ala
abolishes phosphatase activity, but provides a new substrate-trapping mutant. We further show that the nucleophilic Cys459 is not involved in
substrate trapping by Thr466Ala-SHP2 (T/A-SHP2). Mutation of Thr466 does not cause significant structural changes in the active site as revealed
by the trapping of the epidermal growth factor receptor (EGFR), the physiological substrate of SHP2, and by orthovanadate competition
experiments. Based on these results and previous other works, we propose that the role of Thr466 in the catalytic process of SHP2 could be
stabilizing the sulfhydryl group of Cys459 in its reduced state, a state that enables nucleophilic attack on the phosphate moiety of the substrate.
The T/A-SHP2 harbors a single mutation and specifically interacts with the EGFR. Since the nucleophilic Cys459 and the proton donor Asp425
are intact in the T/A-SAHP2, it offers an excellent starting material for solving the structure of SHP2 in complex with its physiological substrate.
© 2005 Elsevier B.V. All rights reserved.Keywords: SHP2; Phosphatase; EGFR; Substrate trapping1. Introduction
Protein Tyr phosphorylation serves as one of the mechanisms
for signal transduction induced by the binding of growth
factors, cytokines or the extracellular matrix to cognate
receptors. It has become evident that dephosphorylation
reactions are as important as phosphorylation reactions. The
enzymes that catalyze phosphorylation reactions are either the
receptors themselves with intrinsic tyrosine kinase activity,
known as receptor tyrosine kinases (RTKs) or cytoplasmic
tyrosine kinases that are recruited to the plasma membrane upon
stimulation [1–3]. On the other hand, dephosphorylation
reactions are catalyzed by a family of enzymes called
phosphotyrosyl phosphatases (PTPs). PTPs are classified as⁎ Corresponding author. Tel.: +1 304 293 7756; fax: +1 304 293 6846.
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doi:10.1016/j.bbamcr.2005.11.013transmembrane or cytoplasmic based on their localization
within the cell under basal conditions [4]. Alternatively, they are
classified as classical PTPs, those specific to Tyr(P) or dual-
specificity PTPs, those that catalyze Tyr(P), Thr(P) and Ser(P)
dephosphorylation reactions [4–6].
The mammalian Src homology 2 phosphotyrosyl phospha-
tase 1 and 2 (SHP1 and SHP2) belong to the cytoplasmic
classical PTPs [7]. The identifying feature of SHP1 and SHP2
is the presence of two tandemly-arranged SH2 domains in their
N-terminal region [8,9]. SHP2 is a ubiquitously expressed
mammalian PTP, whereas SHP1 is primarily restricted to
hematopoietic cells [6,9–11]. SHP1 and SHP2 show significant
structural homology both in the SH2 and PTP domains, but play
opposite physiological roles. SHP1 is a negative regulator of
tyrosine kinase signaling, whereas SHP2 is primarily a positive
effector [4,6,12]. The Drosophila melanogaster PTP, Cork-
screw, also is an SH2 domain-containing PTP with functional
Fig. 1. The active site consensus motif or signature motif of six classical PTPs is
shown. SHP2, SHP1, Corkscrew or R-PTPα has a Thr (T), while PTP1B or
VHR has a Ser (S) residue immediately C-terminal to the invariant Arg (R). In
the signature motif, Cys (C) acts as a nucleophile and R as a phosphate
coordinator.
46 R. Merritt et al. / Biochimica et Biophysica Acta 1763 (2006) 45–56similarity to SHP2 [13–15]. Several lines of evidence show that
SHP2 is important for normal growth and development [16–
18]. However, the molecular mechanism of SHP2 in various
signaling pathways is poorly understood. One of the major
stumbling blocks in SHP2 studies has been that its physiological
substrates have not been identified. To overcome this hurdle, a
substrate-trapping mutant of SHP2 termed DM-SHP2 (DM for
D425A/C459S double mutant) was recently developed [19].
Using this substrate-trapping mutant a molecular mechanism for
SHP2 in the epidermal growth factor receptor (EGFR) signaling
pathway has been described [19].
SHP2 possesses the common structural features found in the
PTP domains of all classical PTPs- the active site consensus
motif (also called the signature motif) identified as H/V–C–X5–
R–S/T and the W–P–D loop [4,20]. Currently, it is believed that
most PTPs follow the same catalytic principle in depho-
sphorylating Tyr(P) on target substrates. The same could be true
for SHP2 given the presence of all the necessary residues for
phosphatase (PTPase) activity. Upon binding of a substrate to
the active site, the invariant Cys residue makes a nucleophilic
attack on the phosphoester bond. This leads to the cleavage of
the phosphate moiety from the target Tyr residue and the
formation of a cysteinyl–phosphate intermediate [20]. The Asp
residue in the W–P–D loop donates a proton to satisfy the
requirements for the leaving phenolate group. The deprotonated
Asp then acts as a general base and activates a water molecule,
which will induce the hydrolysis of the cysteinyl–phosphate
intermediate [21]. In addition, the conserved Gln residue C-
terminal to the signature motif has been proposed to be involved
in the hydrolysis of the cysteinyl–phosphate intermediate [22].
The invariant Arg residue mediates substrate binding into the
active site by coordinating the phosphate moiety. Recently, it
was demonstrated that substitution of Arg465 with Glu
abrogates the substrate binding ability of SHP2 and renders
the enzyme inactive [19] confirming the universal role of Arg in
the signature motif of PTPs.
Based on the above catalytic principle, substrate-trapping
mutants of several PTPs have been produced by mutation of the
W–P–D loop Asp to Ala [23,24]. In contrast, a corresponding
mutation in SHP2 (Asp425Ala) does not provide a substrate-
trapping mutant [19,25]. Although these results cannot rule out
the role of Asp425 in the catalytic process of SHP2, they
definitely indicate the presence of additional players, which are
not yet defined. All classical PTPs, including SHP2, possess a
Thr or a Ser immediately C-terminal to the invariant Arg
residue; SHP2 has a Thr at this position (Thr466) [4,26–30].
The same is true for SHP1, Corkscrew and R-PTPα. On the
other hand PTP1B and vaccinia H1-related (VHR) have a Ser
residue at this position (Fig. 1). In VHR, it was suggested that
the Ser residue mediates the hydrolysis of a cysteinyl–
phosphate intermediate during the dephosphorylation reaction
[31]. In the current report, we set out to determine the
importance of The466 in the catalytic process SHP2. By
employing site-directed mutagenesis, substrate-trapping studies
and PTPase assays, we demonstrate that mutation of Thr466 to
Ala abolishes the PTPase activity of SHP2, but provides a new
substrate trapping mutant, which is as efficient as the DM-SHP2previously reported [19]. In addition, this mutation does not
affect substrate specificity as revealed by the trapping of the
epidermal growth factor receptor (EGFR), the physiological
substrate of SHP2.
2. Materials and methods
2.1. Cells, cell culture, antibodies, etc.
The cell types used in this study were COS-1 and NIH-3T3. All cell types
were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented
with 10% foetal calf serum (FCS), and maintained at 37 °C with 7% CO2. The
Epidermal growth factor (EGF) was purchased from GIBCO-BRL, anti-EGFR
monoclonal antibody from Upstate Biotechnologies, anti-PTP1D (SHP2) from
Pharmagen, and anti-Tyr(P) monoclonal antibody from Cell Signaling. The
polyclonal antibody against SHP2 was raised by injection of rabbits with GST
fusion of the N-terminal region [32]. Horseradish peroxidase-conjugated
secondary antibodies were purchased from Amersham.
2.2. Plasmid construction and site-directed mutagenesis
The construction of plasmids that express WT-SHP2, Asp425Ala-SHP2,
Cys459Ser-SHP2 and Asp425Ala/Cys459Ser-SHP2 was described previously
[19,32]. Hereinafter, these mutants are referred to asWT-SHP2, D/A-SHP2, C/S-
SHP2 and DM-SHP2 (DM for double mutant), respectively. T466A-SHP2 and
C459S/T466A-SHP2mutants hereinafter referred to as the T/A-SHP2 and the C/
S-T/A-SHP2, respectively, were produced by introducing the indicated point
mutation in the WT- or the C/S-SHP2 background using the following primers
that span the signature motif. The sense primer was 5′-CTGCAGTGCTG-
GAATTGGCCGG-GCAGGGACGTTCATTGTG-3′ and the anti-sense primer
was 5′-CACAATGAACGTCCCTGCCCGGCCAATTCCAGC-ACTGCAG-3′.
The Stratagene site-directed mutagenesis kit and protocol was used to produce
these mutants. Introduction of the point mutation was confirmed by sequencing
the relevant region. The glutathione S-transferase fusion of the PTP domain of the
WT-, the T/A-, the C/S-T/A- or the DM-SHP2 protein was constructed by PCR
amplification of the corresponding PTP domains, and ligation into the pGEX-KG
vector at BamHI and HindIII sites. The sense primer containing BamHI
restriction endonuclease site was 5′-AATTTTGGATCCCCCCTTAACAC-
GACTCGTATAAATG-3′, and the anti-sense primer containing the HindIII
site was 5′-AAATTTTAAGCTTTCATCTGAAACTTTTC-TGCTGTTGCAT-
C-3′. These fusion proteinswere designated asWT-PTP, T/A-PTP, C/S-T/A-PTP,
and DM-PTP.
2.3. Cell transfection and preparation of lysates
Cells were transfected with various SHP2 constructs using the FuGene
transfection regent as recommended by the manufacturer (Roche). Following
transfection, cells were incubated for ∼36 h, serum-starved for ∼12 h and then
stimulated with 100 ng/ml EGF. After washing twice with ice-cold PBS, cells
were lysed in 20 mM Tris–HCl pH 7.4 buffer containing 150 mMNaCl, 50 mM
NaF, 1 mMEDTA, 10% glycerol, 1% triton-X-100, 1 mMNa orthovanadate and
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15,000×g at 4 °C and analyzed as desired.
2.4. PTPase assay
The PTPase activity of the various GST fusion proteins was performed with
slight modification of the previously described protocol [31,33]. Briefly, GST-
PTPs were purified on glutathione sepharose beads as recommended by the
manufacturer (Pharmacia), and quantified by measuring absorbance at 280 nm
and comparison with BSA standards. Para-nitrophenyl phosphate (pNPP)
(Biomol) was used as an artificial substrate to determine the PTPase activity of
each GST-PTP. Reactions were performed at 30 °C in 100 μl volume of PTPase
buffer containing 50 mM sodium acetate (for pHs 3.0–5.5) or 25 mM Tris–HCl
(for pHs 6.0–9.0), 50 mM NaCl, 2 mM EDTA and 10 mM dithiothreitol (DTT).
Change in absorbance was followed in a plate-reading visible spectrophotometer
(TECAN) at 405 nm.
2.5. Immunoprecipitation and immunoblotting
Cleared cell lysates were incubated with anti-SHP2 polyclonal antibody
overnight at 4 °C with an additional incubation for 1 h after addition of protein-A
sepharose beads. The precipitates were washed 3 times with cell lysis buffer,
eluted by boiling with Laemmli sample buffer, and then separated on 10%
denaturing polyacrylamide gel. After transfer onto nitrocellulose membrane,
blocking was done by incubation with 3% bovine serum albumin. Membranes
were then stained with the primary antibody either overnight at 4 °C or for 2 h at
room temperature. The secondary antibody staining was for 1 h at room
temperature. The chemiluminescence detection method was used for all Western
blot experiments.
2.6. Affinity precipitation studies
The GST-fusion of the PTP domains of the various SHP2 mutants were
prepared as described previously [19,34]. For affinity precipitation, GST fusion
proteins were first captured on glutathione sepharose beads by incubation of
cleared bacterial lysates (∼1 μg GST-PTP) for 30 min at 4 °C [19,34]. Captured
proteins were washed three times with bacterial lysis buffer and two times with
eukaryotic cell lysis buffer. Cell lysates from COS-1 or NIH-3T3 were then
added to beads and incubated for 1 h at 4 °C, washed five times with cell lysis
buffer, and eluted by boiling for 10 min with Laemmli sample buffer. Separation
of proteins and immunoblot analysis was as described above.
3. Results
Most classical PTPs possess a conserved Ser or Thr residue
immediately C-terminal to the invariant Arg in the active site
signature motif (Fig. 1) [4,26–30]. In the dual specificity
phosphatase VHR (for vaccinia H1-Related), the Ser residue in
this position (Ser131) was shown to be important for enzyme
turnover [31]. SHP2 has a Thr at this position (Thr466), but its
relevance in the catalytic process of this enzyme has not been
addressed. Thus, we investigated the importance of Thr466 in
the catalytic process of SHP2 by a combination of in vitro
PTPase assays, site-directed mutagenesis and substrate-binding
studies in the presence or absence of PTP inhibitors.
3.1. The T/A-SHP2 protein is a PTPase-dead mutant
T/A-SHP2 was produced by site-directed mutagenesis as
described in the materials and methods. The consequence of
this mutation on the PTPase activity of SHP2 was tested in two
ways—by determining its state of Tyr phosphorylation
following EGF stimulation and by in vitro PTPase assays.SHP2 becomes phosphorylated on Tyr542 and Tyr580 upon
stimulation of cells with growth factors or serum [13,35,36],
and as a mechanism of autoregulation, it dephosphorylates itself
immediately [37]. We used this phenomenon as an initial test
for the PTPase activity of the T/A-SHP2. The DM-SHP2 [19]
and the C/S-SHP2 [38,39] were used as PTPase-dead controls,
while the WT-SHP2 and the D/A-SHP2 as positive controls.
These constructs were transiently expressed in COS-1 cells and
EGF-induced Tyr phosphorylation and autodephosphorylation
were determined by immunoblotting with anti-Tyr(P) antibody.
The T/A-SHP2, like those devoid of the nucleophilic Cys459
(C/S-SHP2 or DM-SHP2), was highly Tyr phosphorylated in
EGF-stimulation-dependent manner (Fig. 2A, top panel). As
reported previously, the Tyr phosphorylation of the D/A-SHP2
mutant was similar to that of the WT-SHP2 protein [19].
Moreover, the Tyr phosphorylation state of the EGFR, the only
characterized SHP2 substrate, and the three other potential
substrates previously identified as p90, p120 and p150, was
higher in the T/A-, the C/S- and the DM-SHP2 cells. In fact, the
phosphorylation of p90 and p150 was undetectable in vector,
WT-SHP2 and D/A-SHP2 cells. Reblotting the membrane with
anti-EGFR antibody showed that there was no difference in the
amount of this protein loaded to each lane (Fig. 2A, middle
panel). Further reblotting with anti-SHP2 antibody showed that
the expression of the different SHP2 proteins was comparable
(Fig. 2A, bottom panel). These results suggest that the T/A-
SHP2 could be PTPase defective.
Because autodephosphorylation alone is insufficient to
conclude that the T/A-SHP2 protein is inactive, we conducting
in vitro PTPase assays. We used purified PTP domains (GST
fusions) of the WT- or the T/A-SHP2 protein as an enzyme and
para-nitrophenyl phosphate (pNPP) as an artificial substrate
(see materials and methods). First, PTPase assays were
conducted at different pH points in the presence of 1 μg PTP
and a saturating concentration of pNPP (100 mM) to see if the
T/A-PTP and WT-PTP have different pH preferences or
optimum points. For each pH point, reactions containing
pNPP only were used as negative controls. The reactions
were followed with absorbance measurement (OD) at 405 nm in
a plate reader spectrophotometer (TECAN). Absorbance at 5
min time point was used to compare the effect of pH on enzyme
activity. As shown in Fig. 2B, there was no detectable activity in
the T/A-PTP and control samples at any pH points tested. On
the other hand, the WT-PTP showed a sharp increase in
absorbance at pH 5.0, reached maximum at pH 7.0, and
declined sharply after that, providing a typical bell-shaped curve
with narrow range. To test if time could be a factor on the
PTPase activity T/A-PTP, the absorbance values at pH 7.0 were
plotted against time. Again, the T/A-PTP did not show any
activity at all time points tested, while the WT-PTP exhibited a
steady increase with time (Fig. 2C). Further kinetic analysis
could not be conducted simply because the T/A-PTP was
enzymatically inactive. These results demonstrate that Thr466 is
required for the catalytic activity of SHP2. Furthermore, they
demonstrate that maximum PTPase activity of SHP2 occurs at
pH 7.0, a pH that corresponds to the cytosolic milieu. Given the
complete loss of PTPase activity, the role of Thr466 in SHP2
Fig. 2. Effect of Thr466Ala mutation on the PTPase activity of SHP2. (A) The
indicated SHP2 proteins were transfected into COS-1 cells. After incubation for
∼36 h in growth medium and ∼12 h in serum-free medium, cells were
stimulated with 100 ng/ml EGF for 10 min and lysed. Total cell lysates were
separated by SDS-PAGE and analyzed by immunoblot with the indicated
antibodies. Note that the C/S-the T/A- or the DM-SHP2 mutant is hypertyrosyl
phosphorylated. PTPase assays using para-nitrophenol phosphate (pNPP) as a
substrate at different pH points (B) or time points (C) are depicted in graphs. The
PTPase activity of the WT-PTP or T/A-PTP was determined by measuring
absorbance (production of para-nitrophenol) at 405 nm in a plate reader
spectrophotometer. Three independent experiments were performed in each
case, and the results were plotted absorbance versus pH in B or absorbance
versus time (min) in C.
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intermediate as proposed for VHR.
3.2. T/A-SHP2 is a substrate-trapping mutant
As demonstrated above, the T/A-SHP2 protein is a PTPase-
dead mutant. Loss of PTPase activity could emanate from loss of
substrate binding or inability to hydrolyze the phosphodiester
bond. To gain some insight on this point, we tested the ability of
the T/A-SHP2 to bind to the physiological substrate of SHP2, the
EGFR. Lysates prepared as in Fig. 2Awere immunoprecipitated
with anti-SHP2 antibody and analyzed by immunoblot with the
indicated antibodies. Similar to the DM-SHP2 protein reported
previously [19], the T/A-SHP2 protein trapped p170, which
represents the EGFR, and three other unknown phosphotyrosyl
proteins identified as p150, p120 and p90 (Fig. 3A, top). The
C/S-SHP2 also trapped the EGFR, p150 and p120, but as
compared to the T/A- or the DM-SHP2, it was inefficient. Its
inefficiency was more apparent when it failed to trap the less-
abundant p90. On the other hand, the WT- or the D/A-SHP2
protein exhibited a much lower binding to p170 (EGFR), but not
others. Again, the tyrosine phosphorylation of p70, which
represents SHP2, was higher in the T/A-, the C/S- and the DM-
SHP2 proteins. The identity of p170 and p70 was confirmed by
reblotting the same membrane with anti-EGFR and anti-SHP2
antibodies (Fig. 3A, middle and bottom panels, respectively).
The anti-EGFR monoclonal antibody blot that recognizes a
single epitope better demonstrates the trapping efficiency of the
T/A- or the DM-SHP2 and the inefficiency of the C/S-SHP2
than the anti-Tyr(P), which recognizes multiple epitopes
(compare top and middle panels, Fig. 3A). These results suggest
that although the T/A-SHP2 protein is a PTPase-dead mutant, it
retains its substrate-binding property. Given the similarity in
substrate binding efficiency between the T/A-SHP2 and DM-
SHP2, it is highly likely that the T/A-SHP2 is another substrate-
trapping mutant. In conformity with our previous report [19], the
D/A-SHP2 protein behaved like the WT-SHP2 in its interaction
with the EGFR and in its level of Tyr phosphorylation.
Substrate trapping refers to a stable interaction between a
target substrate and a mutant PTP domain. The results presented
in Fig. 3A show that some amount of the EGFR protein was
coprecipitated with the WT- or the D/A-SHP2 protein. This
could be due to SH2 domain-mediated interactions since the PTP
domains of these proteins are PTPase active, and thus cannot trap
substrates. To confirm this assumption, the PTP domains of the
indicated SHP2 proteins were produced as GST-fusions (see
materials andmethods) and used to affinity precipitate the EGFR
from COS-1 cell lysates stimulated with EGF. As expected, the
EGFR was affinity precipitated by the T/A-PTP and the DM-
PTP. The C/S-PTP also precipitated the EGFR, but when
compared with the T/A-PTP or DM-PTP, it was significantly
lower. On the other hand, there was basal precipitation by WT-
PTP or the D/A-PTP and negligible by the GST alone (Fig. 3B,
top). Reblotting with anti-Tyr(P) antibody showed that the three
other as yet unidentified phosphotyrosyl proteins also were
affinity precipitated by T/A- or DM-PTP suggesting that they
directly interact with the PTP domain (Fig. 3B, middle panel).
Fig. 3. Substrate binding studies. A) COS-1 cells were transfected with the
indicated SHP2 proteins, incubated for 36 h, serum starved for 12 h, and then
stimulated with 100 ng/ml EGF. Lysates prepared from these cells were subjected
to immunoprecipitation (IP) with anti-SHP2 and immunoblotting (IB) with anti-
Tyr(P) (top panel), anti-EGFR (middle panel) or anti-SHP2 (bottom panel)
antibody. (B) Affinity precipitation studies. COS-1 cells were grown to
confluency, serum starved for 12 h and then stimulated with EGF for 10 min.
Lysates prepared from these cells were affinity precipitated (AP) with the
indicated GST fusions of the PTP domains. The precipitates were then analyzed
by immunoblotting with anti-EGFR (top panel), anti-Tyr(P) antibody (middle
panel) or anti-GST (bottom panel) antibody. Band densities of EGFR precipitated
with the different GST fusion protein is shown at the top of the top panel.
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confirmed that the amount of all PTP domains used was
comparable (Fig. 3B, bottom panel). These results confirm that
the coprecipitation of EGFR with the WT- or the D/A-SHP2
proteins was due to interaction via the SH2 domains. Therefore,
the T/A-SHP2 protein represents a new substrate-trapping
mutant.
3.3. Effect of orthovanadate on substrate trapping
Orthovanadate (OV) competitively inhibits PTPs by binding
to the active site of these enzymes. As a result, it is routinelyused as an inhibitor of PTPs in both in vitro and in vivo studies
[40,41]. To evaluate whether this protocol could fit to our
experimental conditions, we first tested the efficiency of OV in
increasing Tyr phosphorylation of cellular proteins in intact
cells. We treated serum-starved COS-1 cells with varying
concentration of OV for 30 min and performed anti-Tyr(P) blot
analysis of total cell lysates. As shown in Fig. 4A, OV increased
Tyr phosphorylation in a concentration-dependent manner in
the absence of EGF stimulation. Thus, it does cross the PM and
inhibit PTPs. Anti-actin reblotting showed that there was no
difference in the amount of total protein loaded to each lane.
Next, we investigated the effect of OVon substrate trapping by
SHP2 proteins. COS-1 cells transiently expressing WT-SHP2,
T/A-SHP2 or DM-SHP2 proteins were serum starved, treated
with OVand then stimulated with EGF for 10 min. Samples not
treated with OV or EGF were also included as controls. To
determine pattern of Tyr phosphorylation under these condi-
tions, total cell lysates were analyzed by immunoblotting.
Clearly, addition of OV over EGF provides an increase in
number and intensity of phosphorylated proteins even in cells
overexpressing WT-SHP2 (Fig. 4B, top panel). Reblotting with
anti-SHP2 antibody indicated that all constructs were expressed
equally (Fig. 4B, bottom panel). These lysates were subjected to
immunoprecipitation with anti-SHP2 and immunoblotting with
anti-EGFR antibodies. OV did not affect the trapping of the
EGFR by the T/A- or the DM-SHP2 protein up to 5 mM, but
inhibited by approximately 50% at 10 mM (Fig. 4C, top panel).
The interaction of the WT-SHP2 protein with the EGFR was
unaffected by OV treatment suggesting that it was solely SH2
domain-mediated. Reblotting with anti-SHP2 antibody showed
that amount of SHP2 proteins was comparable (Fig. 4C, lower
panel). These results show that OV does not affect substrate
trapping by the T/A- or the DM-SHP2 proteins at lower
concentrations, but could inhibit if used higher than 5 mM in
COS-1 cells.
The above findings raised an important question of why
more than 5 mM OV was needed to induce an inhibitory effect
on substrate trapping. Although we observed a direct relation-
ship between OV concentration and protein Tyr phosphoryla-
tion, it was difficult to determine how much of extracellularly
added OV could in fact cross the cell membrane. We did not
quantify the concentration of the EGFR (the test substrate) in
our lysates, but we predicted that it was much lower than the OV
used. If that was the case, it could either be that the EGFR has a
much higher affinity for binding to the active site or that the
amount of OV that crossed the plasma membrane and competed
with the EGFR was significantly lower than the amount added.
This prompted us to conduct substrate trapping studies outside
the cell where we can control the concentration of OV. For these
experiments, COS-1 cells were serum starved for ∼12 h, left
untreated or treated with 1 mM OV for 30 min (to protect
phosphorylation sites on EGFR), stimulated with EGF for 10
min and lysed. These lysates were incubated with the GST
fusion of the PTP domain of the WT-, the T/A- or the DM-SHP2
protein in the absence or presence of varying concentration of
OV. The precipitates were analyzed by immunoblotting with
anti-EGFR antibody. As expected, the T/A- and DM-PTP
Fig. 4. Orthovanadate treatment studies. (A) Serum-starved COS-1 cells were treated with the indicated amounts of orthovanadate (OV) for 30 min. Lysates prep d from these cells were analyzed by immunoblotting
with anti-Tyr(P) antibody (top panel). An anti-actin blot is included as a loading control (bottom panel). (B) The indicated SHP2 constructs were transiently exp ed in COS-1 cells as described in Fig. 2. After serum
starvation, cells were left untreated or treated with the indicated amounts of OV for 30 min by adding in the medium. They were then left unstimulated or stimula with EGF for 10 min. Total cell lysates prepared from
these cells were analyzed for effect of OV on Tyr phosphorylation of cellular proteins and expression of the different SHP2 proteins. (C) The lysates in B wer bjected to immunoprecipitation with anti-SHP2 and
immunoblot analysis with anti-EGFR antibodies to determine OV's effect on substrate trapping. (D) Effect of OVon affinity precipitation of the EGFR by the T fusion of the PTP domains of the indicated SHP2
proteins out side the cell. Numbers above the EGFR blot are band densities to better depict effect of OV.
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intensity measurements, the trapping was unaffected at 1 mM.
However, it was 8 and 4 fold over basal at 2 and 5 mM,
respectively, and only basal at 10 mM (Fig. 4D, top panel).
Reblotting the membrane with anti-GST antibody showed that
there was no difference in the amount of GST fusion proteins in
each lane (Fig. 4D, lower panel). Therefore, OV competitively
inhibits substrate trapping by the T/A- or the DM-SHP2 protein.
Furthermore, these results suggest that mutation of Th466 does
not cause structural changes that interfere with substrate
binding.
3.4. Mechanism of substrate trapping by the T/A-SHP2 protein
As demonstrated above, the T/A-SHP2 protein is a PTPase-
dead, but a substrate-trapping mutant. The next logical step was
to investigate the role of Thr466 in the catalytic process of
SHP2. We addressed this question by site-directed mutagenesis,
substrate binding and pervanadate treatment studies. In the
active site of SHP2 and other PTPs, the Cys residue acts as a
nucleophile, while the Arg as a phosphate coordinator. Mutation
of the Cys residue to Ser in SHP2 provides a weaker substrate-
trapping mutant that also acts as a dominant-negative protein
[20,38,39], while mutation of Arg to Glu gives rise to a
dominant-negative protein with no substrate-binding property
[42]. In other PTPs, mutation of the WPD loop Asp to Ala alone
provides substrate trapping mutants [23,24,43], but not in SHP2
[19]. Substrate trapping by the Asp-to-Ala mutants was shown
to be due to accumulation of a cysteinyl phosphate intermediate
[23,44], a covalently-linked intermediate between the thiolate
group of Cys and the phosphate group of the substrate. As a
result, these mutants show initial PTPase activity until all
enzyme molecules are occupied. The same was true for
Ser131Ala mutant of VHR [31]. In case of T/A-SHP2, however,
total loss of PTPase activity indicates that the role of Thr466
might not be mediating the hydrolysis of a transition-state
complex since no initial para-nitrophenol production was
observed in the in vitro PTPase reactions (see Fig. 2B and C).
Although these results argue against accumulation of a cysteinyl
phosphate intermediate, loss of enzymatic activity alone is
insufficient to exclude the involvement of Cys in substrate
trapping by the T/A-SHP2. Therefore, we reasoned that specific
inactivation of Cys459 in the background of T/A-SHP2 might
provide insights on the mechanism of substrate trapping. Thus,
we introduced a Cys459Ser mutation in the background of T/A-
SHP2, hereinafter referred to as the C/S-T/A-SHP2 and
conducted substrate-trapping studies. The T/A-, the C/S-T/A-
or the DM-SHP2 protein was expressed in COS-1 cells, and the
ability of each protein to trap the EGFR was compared. The
WT-SHP2 protein was used as a negative control. These
experiments were conducted in time-course fashion to evaluate
the stability of enzyme-substrate complex following EGF
stimulation. Initial analysis of total cell lysates showed that
the T/A-, the C/S-T/A- and the DM-SHP2 proteins were highly
phosphorylated owing to their inability to autodephosphorylate
themselves (Fig. 5A, top panel). Reblotting with anti-SHP2
antibody showed that amount of SHP2 protein in all lanes wascomparable (Fig. 5A, bottom panel). Immunoprecipitation with
anti-SHP2 and immunoblotting with anti-EGFR antibody
demonstrated that the C/S-T/A-SHP2 protein trapped the
EGFR as efficiently as the T/A- or the DM-SHP2 protein
(Fig. 5B, top panel). In addition, the enzyme–substrate complex
was stable for at least 120 min following EGF stimulation. On
the other hand, the WT-SHP2 protein showed low level of
interaction that decreased over the 2-h stimulation period.
Reblotting the membrane with anti-SHP2 antibody showed that
there was no difference in the amount of each SHP2 protein
recovered during the immunoprecipitation reaction (Fig. 5B,
bottom panel). Thus, introduction of the Cys459Ser mutation
into the T/A-SHP2 did not affect the trapping property
suggesting that Cys459 may not contribute to this phenomenon.
However, these findings could potentially be complicated by the
fact that the C/S-SHP2 protein by itself exhibits some level of
substrate trapping. To complement these findings, pervanadate
(PV) treatment studies were conducted (see below).
Substrate trapping by the Asp-to-Ala mutants of other PTPs
was proposed to be due to accumulation of a cysteinyl–
phosphate intermediate [23,24,43]. As such, these mutants
exhibit sensitivity to the oxidative inhibitor pervanadate (PV)
suggesting that the Cys residue is important for their trapping
property [45,46]. Given the efficiency of the C/S-T/A-SHP2
mutant, the presence of Cys459 did not seem to be important
for trapping by the T/A-SHP2. However, it is possible that the
T/A-SHP2 on one hand and the C/S-T/A-SHP2 on the other
may utilize different mechanisms to trap target substrates
where Cys459 is necessary only for the T/A-SHP2. If this
were the case, then treatment of cells with PV could abolish
trapping by the T/A-SHP2 due to oxidation of the sulfhydryl
group. Initially, we analyzed the effect of PV on the Tyr
phosphorylation of cellular proteins. As shown in Fig. 5C, PV
enhanced Tyr phosphorylation in a concentration-dependent
manner similar to OV. Next, we tested PV's effect on substrate
trapping by TA-SHP2 protein. The WT-SHP2 and DM-SHP2
proteins were used as negative and positive controls,
respectively. COS-1 cells were transfected with these con-
structs and treated with varying concentration of PV for 30
min prior to EGF stimulation. Analysis of total cell lysates
indicated that PV enhances Tyr phosphorylation under these
conditions too (Fig. 5D, top panel). Reblotting with anti-SHP2
antibody showed that amount of overexpressed SHP2 proteins
was comparable (Fig. 5D, lower panel). These lysates were
subjected to immunoprecipitation with anti-SHP2 and immu-
noblotting with anti-EGFR antibody. As shown in Fig. 5E (top
panel), pervanadate did not affect the trapping of the EGFR by
the T/A-SHP2 or the DM-SHP2 protein even at the higher
concentration used. In fact, it seems to enhance trapping. As
expected, the WT-SHP2 protein precipitated a very low
amount of the EGFR protein that did not change with PV
concentration. Reblotting with anti-SHP2 antibody showed
that the amount of SHP2 proteins in all lanes was comparable
(Fig. 5E, bottom panel). These results indicate that pervana-
date does not affect substrate trapping by the T/A. Assuming
that this could be related to low level of pervanadate crossing
the PM, we conducted in vitro substrate trapping in the
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did not show any effect on substrate trapping even at 10 mM
concentration (data not shown). These results confirm the site-
directed mutagenesis studies (Fig. 5B) that Cys459 does not
contribute to substrate trapping by the T/A-SHP2 protein.
3.5. The T/A- and the C/S-T/A-SHP2 proteins are highly
specific substrate-trapping mutants
The T/A- and the C/S-T/A-SHP2 proteins trap the EGFR as
efficiently as the DM. However, it was not clear if they were
selective for Tyr992(P) of the EGFR, which was demonstrated
to be an SHP2 target [19]. We thus tested the specificity of the
T/A- or the C/S-T/A-SHP2 protein toward Tyr992(P) by affinity
precipitation. Wild type EGFR (WT-EGFR) or Tyr992Phe-
EGFR was expressed in NIH-3T3 cells that have undetectable
level of endogenous EGFR. Cells that were transfected with
vector alone were used as negative controls. After serum
starvation for ∼12 h, cells were stimulated with 100 ng/ml EGF
for 10 min. Immunoblot analysis of total cell lysates with anti-
EGFR antibody showed that both constructs were expressed
comparably (Fig. 6A, top panel). Reblotting with anti-Tyr(P)
antibody further showed that both constructs were Tyr
phosphorylated, but there was a slight reduction in the
Tyr992Phe-EGFR lane reflecting the effect of the mutation
(Fig. 6A, middle panel). Note that EGFR has five major
autophosphorylation sites. As a loading control, we blotted the
same membrane with anti-β-actin antibody (Fig. 6A, lower
panel), which showed the presence of comparable amount of
cellular proteins. These lysates were subjected to affinity
precipitation with the GST fusion of the PTP domain of the T/A,
the C/S-T/A or the DM protein. Precipitates were then analyzed
by immunoblot with anti-EGFR antibody. As shown in Fig. 6B,
these PTP domains affinity precipitated the WT-EGFR, but very
little or none of the Tyr992Phe-EGFR. Reblotting the
membrane with anti-GST antibody showed that there was
comparable amount of the GST fusion protein in each lane.
These results suggest that the T/A- and the C/S-T/A-SHP2
proteins are highly specific substrate-trapping mutants.
4. Discussion
Unlike other PTPs such as PTP1B and SHP1, SHP2 is a
unique PTP in that it positively modulates growth and cell
survival signals induced by RTKs. However, its mechanism of
action has been very difficult to uncover primarily because very
little is known about its target substrates. We have recentlyFig. 5. The role of Cys459 in substrate trapping by the T/A-SHP2 mutant. (A) CO
construct. After incubation for 36 h, cells were serum starved for 12 h and then stim
analyzed by immunoblotting with anti-Tyr(P) (top panel) to examine Tyr phosphory
The same lysates were immunoprecipitated with anti-SHP2 and blotted with anti-EG
1 cells were treated with the indicated amounts of pervanadate (PV) for 30 min. Ef
with anti-Tyr(P) antibody (top panel). An anti-actin blot is included as a loading c
after starvation, cells were left untreated or treated with the different concentration
lysates prepared from these cells were analyzed for effect of PV on Tyr phosphor
panel). (E) The same lysates were subjected to immunoprecipitation with anti-SHP
trapping even at 10 mM.identified the EGFR as a target substrate of SHP2 and have
provided a mechanism in mediating Ras activation in the EGFR
signalling pathway [42]. More recently, a similar mechanism
was proposed for the Gab1-SHP2 axis in RTK-induced Ras
activation [47], an indication of emerging advances in our
understanding of SHP2. In the current report, we show that the
conserved residue in the signature motif of SHP2, Thr466, is
essential for the catalytic activity of SHP2, and that mutation of
Thr466 to Ala provides a new substrate-trapping mutant. As
opposed to the DM- or the C/S-T/A-SHP2 protein, the T/A-
SHP2 is a single mutant making it a preferred material for
substrate identification and structural studies aimed at solving
SHP2 structure in complex with its physiological substrate.
The consensus sequence for the active site signature motif of
six well-known PTPs is shown in Fig. 1. SHP1, SHP2, R-PTPα
and Corkscrew have Thr, while PTP1B and VHR have Ser
immediately C-terminal to the invariant Arg residue in this
motif [4,26–30]. However, very little is known about the im-
portance of the conserved hydroxyl amino acid in the catalytic
process. Previous work on VHR has shown that the cor-
responding Ser residue mediates the hydrolysis of the cysteinyl-
phosphate intermediate [31]. Thus, we hypothesized that Thr466
of SHP2 might function a similar way. This possibility was
investigated by site-directed mutagenesis, PTPase assays and
substrate binding studies. The EGFR system was used as a
model for these studies as it is the physiological substrate of
SHP2 [19,42].
SHP2 becomes Tyr phosphorylated upon stimulation of cells
with a variety of growth factors [13,35,36]. One of the unique
characteristics of SHP2 is that it auto-regulates its own Tyr
phosphorylation [19,37,42]. The anti-Tyr(P) Western blots
presented in Fig. 2A show that the T/A-SHP2 protein was
unable to autodephosphorylate itself suggesting that it is PTPase
defective. These results were further confirmed by PTPase
assays (Fig. 2B and C) that the T/A-SHP2 is in deed a PTPase-
dead mutant even when tested at varying pH and time points.
Therefore, Thr466 is important for the catalytic activity of
SHP2. Total loss of PTPase activity was unexpected given the
previous report on VHR where mutation of the corresponding
Ser residue stalled this enzyme in a transition state. Under those
experimental conditions, an initial burst of pNP formation was
observed. In case of SHP2 however, we were unable to detect
any activity. These differences might be related to the fact that
SHP2 and VHR are two different proteins with different
physiological roles.
Mutation of Asp in the WPD loop stalls PTPs in a tran-
sition state leading to accumulation of a cysteinyl-phosphateS-1 cells were transfected with the WT-, T/A-, the C/S-T/A- or the DM-SHP2
ulated with EGF for 10 min, 1 h or 2 h. Lysates prepared from these cells were
lation or with an anti-SHP2 (bottom panel) antibody to evaluate expression. (B)
FR (top panel) or anti-SHP2 (bottom panel) antibody. (C) Serum-starved COS-
fect of PV on Tyr phosphorylation of cellular proteins was assessed by blotting
ontrol (bottom panel). (D) SHP2 proteins were expressed in COS-1 cells, and
of PV and then unstimulated or stimulated with EGF for 10 min. Total cell
ylation (top panel). An anti-actin blot is shown as a loading control (bottom
2 and immunoblotting with anti-EGFR antibodies. PV did not affect substrate
Fig. 6. Specificity studies. NIH-3T3 cells were transfected with vector alone, WT-EGFR or Tyr992Phe-EGFR (Y/F). After 36 h of incubation, cells were serum starved
for 12 h, and then stimulated with EGF for 10 min. (A) Total cell lysates were analyzed for expression of EGFR (top panel) or Tyr phosphorylation (middle panel).
Anti-actin blot is included as a loading control. (B) The same lysates were subjected to affinity precipitation with the indicated GST fusion PTPs and analyzed by
immunoblot with anti-EGFR (top panel) or anti-GST (bottom panel).
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nucleophilic Cys residue that attacks the phosphate moiety
of the Tyr(P) leading to formation of a covalent bond
[31,44,48,49]. As a result, these mutants become substrate
trapping. Mutation of Ser in the signature motif of VHR, a
residue that corresponds to Thr466 of SHP2, also stalls this
enzyme in a transition state [31] although its ability to trap
target substrates was not investigated. In case of SHP2, we
have demonstrated that the T/A-SHP2 traps the EGFR and the
three other unknown phosphotyrosyl proteins (Fig. 3), same
set of proteins trapped by the DM-SHP2 [19]. Therefore, the
T/A-SHP2 protein is a substrate trapping mutant. The specific
interaction of the T/A-SHP2 protein with target substrates
together with inhibition studies with OV show that mutation
of Thr466 did not cause structural changes that affect substrate
binding. As shown in Fig. 4C and D, OV competitively
inhibited substrate trapping by both the T/A- and DM-SHP2
proteins. 1–2 mM OV both in intact cells and in vitro
enhanced substrate trapping probably by protecting target Tyr
(P) sites, but acted as a competitive inhibitor when used in
excess of this concentration. Thus, substrate trapping solely
using OV as an inducer of Tyr phosphorylation could be
counter productive unless an amount that inhibits binding is
predetermined in each case.
The next logical step was to investigate what role Thr466
plays in the catalytic process of SHP2. In the active site of SHP2
and other PTPs, the Cys residue acts as a nucleophile, while the
Arg as a phosphate coordinator. On the other hand, Asp in the
WPD loop acts as a proton donor for the leaving phenolate
group and as an acceptor in the hydrolysis of the cysteinyl
phosphate intermediate. As a result, its mutation to Ala provides
substrate trapping mutants [23,44]. In PTPase assays, these
mutants show initial activity until all enzyme molecules are
occupied. The same is true for Ser131Ala mutant of VHR [31].
In case of T/A-SHP2 however, there was total loss of PTPase
activity indicating that the role of Thr466 might not be
mediating the hydrolysis of a transition-state complex since
no initial para-nitrophenol production was observed in the in
vitro PTPase reactions (Fig. 2B and C). Clearly, Thr466 isessential for the catalytic process of SHP2. However, what
specific role it might play is not clear.
Next, we investigated the importance of Cys459 in substrate
trapping by the T/A-SHP2 protein. Differently said, we assessed
whether accumulation of a cysteinyl phosphate intermediate
was the mechanism for the T/A-SHP2 protein to trap substrates.
It was reasoned that if nucleophilic attack by Cys459 were
important for substrate trapping by the T/A-SHP2, the C/S-T/A-
SHP2 should be a weaker trapping mutant for the mutation
abolishes the contribution of the T/A leaving only that of the
C/S. However, the C/S-T/A-SHP2 was as efficient as the T/A-
or the DM-SHP2 in substrate trapping (Fig. 5B) suggesting
that Cys459 may not be important. Since the C/S-SHP2 by
itself exhibits substrate-trapping property [20,38,39], our
results with the C/S-T/A cannot completely rule out the
involvement of Cys459. Therefore, we conducted substrate
binding studies in the presence of varying amounts of PV,
which inactivates PTPs by oxidizing the nucleophilic Cys
residue [45,46,50]. In support of the mutagenesis studies, the
T/A-SHP2 trapped the EGFR in the presence of PV both in
intact cells and outside the cell (Fig. 5E and data not shown).
These results show that Cys459 does not contribute to
substrate trapping by the T/A-SHP2, which in turn suggests
that Thr466 is not involved in enzyme turnover. It is possible
that the conserved Ser or Thr residue in the signature motif of
different PTPs may play variable role depending on the
corresponding structural context.
It could be argued that mutation of a conserved residue in the
active site of an enzyme may cause loss of specificity. Our
previous report demonstrate that the DM-SHP2 protein carrying
double mutations (Cys459 in the signature motif and Asp425 in
theWPD loop) maintains specificity toward target substrates [19].
The finding that the T/A-SHP2 protein distinctively recognizes
Tyr992(P)-EGFR demonstrates retention of substrate specificity.
Therefore, the T/A-SHP2 protein is a specific substrate-trapping
mutant. Furthermore, the ability of the T/A-SHP2 protein to
specifically bind to target substrates suggests that Thr466 is not
involved in substrate recognition by the active site. Structural
studies with PTP1B have shown that the corresponding Ser
55R. Merritt et al. / Biochimica et Biophysica Acta 1763 (2006) 45–56residue (Ser222) makes a hydrogen bond with the Sγ atom of the
nucleophilic Cys [49]. Similarly, the corresponding Ser residue in
the low molecular weight PTP was proposed to participate in
stabilizing the nucleophilic Cys [48]. Our findings on SHP2 seem
to concur with these studies. Given that the mutation totally
abolished enzyme activity at all pH points tested, and that this
mutation did not affect specific interactions with target substrates,
we propose that the role of Thr466 in the catalytic process of
SHP2 is to stabilize the sulfhydryl group of Cys459 for
nucleophilic attack on the phosphate moiety of the substrate.
Obviously, further structural studies are required to verify this
point. The development of the T/A-SHP2 substrate-trapping
mutant with intact nucleophile (Cys459), proton donor and
acceptor (Asp425) and the identification of the Tyr992(P) of the
EGFR as a substrate of SHP2 [19,42] will provide an excellent
starting material for such studies.Acknowledgements
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